A systematic review of the current application status of decision-analytical models in the pharmacoeconomic evaluation of targeted therapies for pulmonary arterial hypertension

Dong, Wenxing; Zhang, Zhe; Wang, Xiaodan; Ma, Xiaolong; Chu, Mingming; Li, Yulian; Xiang, Xing; Peng, Cheng; Zhang, Rong

doi:10.1186/s12962-025-00621-z

Cost Effectiveness and Resource Allocation

Table 2 Summary of identified studies

From: A systematic review of the current application status of decision-analytical models in the pharmacoeconomic evaluation of targeted therapies for pulmonary arterial hypertension

Study	Year	Country	Population	Intervention and comparator	Techniques of economic evaluation
Margaret C. Garin [13]	2009	US	PAH	Bosentan, sitaxsentan, ambrisentan, sildenafil, iloprost, treprostinil and epoprostenol (compare with each other)	CUA
Y-F Chen [12]	2009	UK	PAH	Iloprost, epoprostenol, bosentan, sitaxsentan, sildenafil vs. Supportive treatment^a	CEA
Antonio Roman [14]	2012	Spain	PAH	Iloprost, treprostinil and epoprostenol (compare with each other)	CEA/CUA
CADTH [15]	2015	Canada	PAH	1. Bosentan, ambrisentan, sildenafil, tadalafil, riociguat, epoprostenol vs. supportive treatment 2. ERA plus tadalafil vs. ERA plus placebo 1. 3. ERA plus riociguat vs. ERA plus placebo	CUA
Watsamon Thongsri [18]	2015	Thailand	PAH-CHD	1. Beraprost plus supportive treatment vs. supportive treatment 2. Sildenafil plus iloprost vs. sildenafil plus supportive treatment 1. 3. Sildenafil plus bosentan vs. sildenafil plus supportive treatment	CUA/BIA
Fan [17]	2016	China	PAH	Bosentan vs. supportive treatment	CUA
Kathryn Coyle [16]	2016	Canada	PAH	Bosentan, ambrisentan, sildenafil, tadalafil, riociguat vs. supportive treatment	CEA
CADTH [19]	2017	Canada	PAH	Selexipag plus background treatment vs. background treatment^b	CUA
Oktavia Lilyasari [20]	2019	Indonesia	PAH	Sildenafil vs. beraprost	CUA
Marzieh Nosrati [21]	2020	Iran	PAH	Macitentan vs. bosentan	CUA
Zhao [22]	2022	China	PAH	Bosentan, ambrisentan, macitentan sildenafil, tadalafil vs. supportive treatment	CEA
Mahna Ekhlasi [23]	2023	Iran	PAH	Macitentan vs. bosentan	CUA
Dong [24]	2023	China	PAH	Selexipag plus ERA and PDE5i vs. ERA plus PDE5i	CUA

^{a Supportive treatment comprised anticoagulation, administration of cardiotonic agents, diuretics, and oxygen therapy}
^{b Background treatment encompasses the administration of endothelin receptor antagonists and/or phosphodiesterase-5 inhibitors or the absence of any intervention}
^{PAH Pulmonary arterial hypertension, PAH-CHD Pulmonary arterial hypertension associated with congenital heart disease, ERA endothelin receptor antagonist, PDE5i phosphodiesterase-5 inhibitors, CEA cost-effectiveness analysis, CUA cost-utility analysis, BIA, Budget impact analysis}

Back to article page

ISSN: 1478-7547

Contact us

General enquiries: journalsubmissions@springernature.com